SERACCESS® - DISRUPTIVE TECHNOLOGY FOR THE MONITORING AND CONTROL OF CRITICAL BLOOD PARAMETERS

SERACCESS® MILESTONE 2B

Written by: Dr. A. Tarniceriu

Developing a Novel Automated Intravenous Insulin Delivery System. An In Silico Study Characterizing the Glucose Measurement Effect on the System’s Performance

Authors: Dr. A. Tarniceriu; L. Desborough; Dr. C. Ziemba; Dr. B. Schär; R. Mathys

Accepted at the 14th International Conference on Advanced Technologies and Treatments for Diabetes; June 2021

Keywords: Automated Insulin Delivery, in silico, closed loop

Background

We are developing a blood glucose control technology based on intravenous (IV) blood sampling and delivery of insulin. A wearable device photometrically measures glucose in IV blood samples and delivers insulin via the same IV path. This removes the time lag between the interstitial and blood compartments associated to subcutaneous technologies and ensures faster insulin action. In turn, this facilitates blood glucose control without prior meal or activity information.

Objective

As the performance of the automated glucose measurement is a critical component of automated insulin delivery (AID) systems, we evaluate the effect of measurement delay and error on the time-in-range and time-below-range for type 1 diabetes in-silico subjects.

Method

The simulations are performed on two in silico type 1 diabetes subject models: the UVa/Padova T1DMS model (33 subjects – 11 adults, 11 adolescents, and 11 children) and the NudgeBG model (1000 subjects, including the effect of unmeasured sources of variation such as stress and exercise). For each subject, glucose profiles are simulated for two days involving four meals/day (three main meals and a late-evening snack; 20-70 grams of carbohydrates/meal). Measurement and insulin delivery errors are included in the simulation. The control interval is 15 minutes. The only subject-specific physiology parameter used to configure the control algorithm is the total daily basal dose (TDBD) of insulin. Time in the narrow glycemic range (70-140 mg/dl) and time-below-range (<70 mg/dl) are computed for measurement delays up to 20 minutes and for measurement errors up to 35%.

Results

The result figures display the time-in-range and time-below-range dependency on the measurement delay and measurement error, for the UVa/Padova and NudgeBG models, respectively. As expected, the performance degrades for higher delays and errors. The performance is more sensitive to the measurement delay than to the measurement error.

SPL_MS_2b_Nudge_3_and_4_4d98901499

NudgeBG results

SPL_MS_2b_Nudge_3_and_4_4d98901499

UVa/Padova results

As the measurement delay increases, the time-in-range decreases. Because IV sampling eliminates the lag between venous and interstitial compartments, it reduces the overall delay, leading to higher performance. Both time-in-range and time-below-range are more sensitive to the measurement delay than to the measurement error.

© Copyright 2021 by Securecell AG. All rights reserved, including graphs and images. Lucullus and Numera are registered trademarks of Securecell AG, Switzerland.

Dr. A. Tarniceriu

Tags

Share